Antimicrobial resistance in the UK and globally.
Following obtaining an MBChB from Edinburgh University in 2002 I pursued core medical training with a specific interest in infectious diseases working in hospitals in London and Edinburgh and obtaining a Diploma in Tropical Medicine and Hygiene in 2006. I took up a specialist training post in Infectious diseases in 2007 and started a Wellcome Trust research training fellowship from University of Dundee in 2009 where I wrote a PhD on pathogen resistance looking the interaction between arsenic exposure and resistance to antimony in the parasite Leishmania.
My current research focus is in microbial dynamics in antimicrobial resistance with a particular interest in urinary tract infections.
I am also currently working clinically as an Infectious Diseases Specialist Registrar in NHS Lothian hospitals where my role includes antimicrobial stewardship, infection consult rounds, care for inpatients with HIV, Hepatitis, Tuberculosis, community-acquired, hospital-acquired and imported infections.
Ashworth 1, Room 138
Global disease burden due to antibiotic resistance – state of the evidence.
Woolhouse, M., Waugh, C., Perry, M.R. and Nair, H. (2016).
Journal of Global Health 6: 010306.
Clinical implications of antimicrobial resistance
Meghan Perry, Mark Woolhouse
Longevity Bulletin, Institute and Faculty of Actuaries, Issue 8, June 2016
Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India. A retrospective cohort study.
Meghan R. Perry, Vijay K Prajapati, Joris Menten, Andrea Raab, Joerg Feldmann, Dipankar Chakraborti, Shyam Sundar, Alan Fairlamb, Marleen Boelaert, Albert Picado
PLoS Negl Trop Dis 2015 Mar 2;9(3):e0003518.
Chronic arsenic exposure and clinical resistance to antimonial drugs in visceral leishmaniasis: proof of concept in mouse model
Meghan R. Perry, Susan Wyllie, Andrea Raab, Joerg Feldmann, Alan H. Fairlamb
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19932-7
The R enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis
Stephen Patterson, Susan Wyllie, Laste Stojanovski, Meghan R. Perry, Frederick R.C. Simeons, Suzanne Norval, Maria Osuna-Cabello, Manu De Rycker, Raffaella Grimaldi, Kevin D. Read and Alan H. Fairlamb
Antimicrob Agents Chemother. 2013 Oct;57(10):4699-706
Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian Subcontinent?
Meghan R. Perry, Susan Wyllie, Vijay Kumar Prajapati, Joerg Feldmann, Shyam Sundar, Marleen Boelaert, Alan H. Fairlamb
PLoS Negl Trop Dis. 2011 Sep;5(9):e1227
HIV testing – getting the message across: a survey of knowledge, attitudes and practice amongst non-HIV specialist physicians
Ewan Hunter*, Meghan Perry*, Clifford Leen, Nikhil Premchand
Postgrad Med J. 2012 Feb;88(1036):59-65.
*Joint first author
Cytokine Storm in a Phase 1 Trial of the Anti CD-28 Monoclonal Antibody
Ganesh Suntharalingam, Meghan R Perry, Stephen Ward, Stephen J. Brett, Andrew Castello-Cortes, Michael D. Brunner, Nicki Panoskaltsis
N Engl J Med. 2006 Sep 7;355(10) :1018-28.